The deal has no impact because it is really only "significant" to AMBS longs. It's great that they got the monkey of their back and have a LOI from the first intended Lympro user for an ALZ trial. However, Wall Street was not born last night. It's a 32 patient trial that is scheduled for 3rd quarter. So a deal whose revenue might pay the light bill for a year isn't going to sky rocket the stock. HOW AMBS IS GOING TO FUND ELTO 2B AND NEW ACQUISITIONS IS STILL ONE BIG QUESTION MARK?